Free Trial
Mark Massaro

Mark Massaro Analyst Performance

Managing Director, Senior Equity Research Analyst at BTIG Research

Mark Massaro is a stock analyst at BTIG Research, covering 35 publicly traded companies across a range of sectors. Over the past year, Mark Massaro has issued 10 stock ratings, including buy, hold, and sell recommendations. While full access to Mark Massaro's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Mark Massaro's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
295 Last 10 Years
Buy Recommendations
76.82% 222 Buy Ratings
Companies Covered
35 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy76.8%222 ratings
Hold22.8%66 ratings
Sell0.3%1 ratings

Out of 289 total stock ratings issued by Mark Massaro at BTIG Research, the majority (76.8%) have been Buy recommendations, followed by 22.8% Hold and 0.3% Sell.

Exchange Coverage

ExchangePercentageCount
NASDAQ
82.9% of companies on NASDAQ
29 companies
NYSE
14.3% of companies on NYSE
5 companies
OTCMKTS
2.9% of companies on OTCMKTS
1 company

Mark Massaro, an analyst at BTIG Research, currently covers 35 companies listed on NASDAQ, NYSE and OTCMKTS, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
33 companies
94.3%
Computer and Technology
1 company
2.9%
Miscellaneous
1 company
2.9%

Mark Massaro of BTIG Research specializes in stock coverage within the Medical sector, with additional focus on Computer and Technology and companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
17.1%
MEDICAL SERVICES
5 companies
14.3%
MED INSTRUMENTS
4 companies
11.4%
MED PRODUCTS
3 companies
8.6%
MEDICAL INFO SYS
2 companies
5.7%
MEDICAL LABORATORIES
2 companies
5.7%
ANALYTICAL INSTRUMENTS
2 companies
5.7%
SURGICAL & MEDICAL INSTRUMENTS
2 companies
5.7%
DIAGNOSTIC SUBSTANCES
2 companies
5.7%
MED - GENERIC DRG
1 company
2.9%
PHARMACEUTICAL PREPARATIONS
1 company
2.9%
MED - OUTP/HM CRE
1 company
2.9%
SKILLED NURSING CARE FACILITIES
1 company
2.9%
MEASURING & CONTROLLING DEVICES
1 company
2.9%
Miscellaneous
1 company
2.9%
MED/DENTAL - SUPP
1 company
2.9%

About Mark Massaro

Mark Massaro is a Managing Director and BTIG Life Science and Diagnostic Tools Analyst. Prior to BTIG, he served as the Chief Financial Officer at ArcherDX, Inc., an oncology diagnostics and pharmaceutical services company, which was acquired by Invitae Corporation. Previously, Mr. Massaro was a Managing Director and Senior Equity Research Analyst within Diagnostics and Life Science Tools at Canaccord Genuity, where he spent more than eight years focused on high-growth, precision medicine and next-generation sequencing companies, as well as molecular and point-of-care diagnostics, reference labs and animal health. He was named a “Rising Star” in Institutional Investor’s All America Survey for life science and diagnostics tools in October 2016. Earlier in his career, Mr. Massaro was an Associate Equity Analyst within Healthcare Services at Avondale Partners and held corporate finance and financial reporting roles at Dell EMC and Fidelity Investments. He earned an MBA from Babson College and a BA in economics and Spanish from the University of Massachusetts – Amherst.
Follow on LinkedIn

Mark Massaro's Ratings History at BTIG Research

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Lucid Diagnostics Inc. stock logo
LUCD
Lucid Diagnostics
9/5/2025Boost Price Target$1.38$2.50Buy
Guardant Health, Inc. stock logo
GH
Guardant Health
9/4/2025Boost Price Target$59.08$70.00Buy
Ginkgo Bioworks Holdings, Inc. stock logo
DNA
Ginkgo Bioworks
8/25/2025Boost Price Target$12.51$9.00Sell
Tempus AI, Inc. stock logo
TEM
Tempus AI
8/20/2025Boost Price Target$73.08$85.00Buy
Exact Sciences Corporation stock logo
EXAS
Exact Sciences
8/12/2025Lower Price Target$41.52$60.00Buy
MaxCyte, Inc. stock logo
MXCT
MaxCyte
8/11/2025Reiterated Rating$1.38Neutral
Tempus AI, Inc. stock logo
TEM
Tempus AI
8/8/2025Initiated Coverage$58.74$60.00Buy
Personalis, Inc. stock logo
PSNL
Personalis
8/6/2025Set Price Target$4.52$6.00
Tempus AI, Inc. stock logo
TEM
Tempus AI
4/21/2025Initiated Coverage$40.42$60.00Buy
MaxCyte, Inc. stock logo
MXCT
MaxCyte
3/12/2025Set Price Target$3.47$6.00Buy